TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19260800

Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg administered 1 hour before SWL and 24 hours later
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control group (no pretreatment medications)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Rofecoxib
Number of subjects: 69
Study: 17105757

Group type: EXPERIMENTAL
Intervention: Tolvaptan (15 mg daily, increased to 30 mg and then to 60 mg if necessary)
Number of subjects: 448

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: Tolvaptan
Number of subjects: 448
Study: 14675982

Group type: EXPERIMENTAL
Intervention: Oestrogen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (baseline)
Number of subjects: 0
Study: 11502641

Group type: EXPERIMENTAL
Intervention: O(2)WT
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: O(2) administration
Number of subjects: 20

Group type: COMPARATOR
Intervention: BWT
Number of subjects: 20

Group type: COMPARATOR
Intervention: CAWT
Number of subjects: 20
Study: 9010043

Group type: EXPERIMENTAL
Intervention: CODE plus recombinant human granulocyte colony-stimulating factor (rhG-CSF)
Number of subjects: 63

Group type: COMPARATOR
Intervention: CODE alone
Number of subjects: 63
Study: 8303624

Group type: EXPERIMENTAL
Intervention: MK-0679 (825 mg, orally)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 3706879

Group type: EXPERIMENTAL
Intervention: Atropine sulfate (AS) 6.4 mg total (3.2 mg inhaled twice)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Metaproterenol sulfate (MP) 30 mg total (15 mg inhaled twice)
Number of subjects: 21
Study: 30928806

Group type: EXPERIMENTAL
Intervention: Eribulin (1.4 mg/m2, intravenously, on day 1 and day 8)
Number of subjects: 530

Group type: COMPARATOR
Intervention: Vinorelbine (25 mg/m2, intravenously, on day 1, day 8 and day 15)
Number of subjects: 530

Group type: EXPERIMENTAL
Intervention: Eribulin
Number of subjects: 530

Group type: COMPARATOR
Intervention: Vinorelbine
Number of subjects: 530
Study: 28601821

Group type: EXPERIMENTAL
Intervention: Golimumab plus celecoxib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Golimumab alone
Number of subjects: 0
Study: 25650561

Group type: EXPERIMENTAL
Intervention: Aided modeling intervention with contrastive targets through concentrated modeling and interactive play activities.
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Aided modeling intervention with contrastive targets.
Number of subjects: 3
Study: 23229908

Group type: EXPERIMENTAL
Intervention: Too much perceived decision-making responsibility
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Not enough perceived decision-making responsibility
Number of subjects: 368

Group type: COMPARATOR
Intervention: Reasonable amount of perceived decision-making responsibility
Number of subjects: 368
Study: 22084195

Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of 150 × 10(6) autologous bone marrow mononuclear cells (BMCs)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of 150 × 10(6) autologous BMCs
Number of subjects: 87
Study: 19407945

Group type: EXPERIMENTAL
Intervention: Intravenous dripping of Qingkailing Injection in combination with oral intake of Er'tong Qingfei Oral Liquid
Number of subjects: 206

Group type: COMPARATOR
Intervention: Intravenous dripping of ribavirin injection in combination with oral intake of potassium guaiacol sulfonate oral liquid
Number of subjects: 206
Study: 16465090

Group type: EXPERIMENTAL
Intervention: Geriatric Competencies for RNs in Hospitals
Number of subjects: 0
Study: 14671151

Group type: EXPERIMENTAL
Intervention: 200-300 microTesla, 50 Hz circularly polarized magnetic field for 2 hours
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 19
Study: 10736973

Group type: EXPERIMENTAL
Intervention: Dexamethasone (2 mg/day in 4 divided doses for 3 days)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Dexamethasone (2 mg/day in 4 divided doses for 3 days) plus Pyridostigmine (120 mg p.o.)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Dexamethasone (2 mg/day in 4 divided doses for 3 days) plus MCP (2.5 mg in an i.v. bolus injection)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Dexamethasone (2 mg/day in 4 divided doses for 3 days) plus Pyridostigmine (120 mg p.o.) plus MCP (2.5 mg in an i.v. bolus injection)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 9119934

Group type: COMPARATOR
Intervention: Normal children
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical groups (autism, MR, Down syndrome)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MR group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Individuals with autism
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Individuals with MR
Number of subjects: 0
Study: 1353742

Group type: EXPERIMENTAL
Intervention: 20 ml HiEPA fish oil (4.5 g of eicosapentaenoic acid) daily for one year
Number of subjects: 87

Group type: COMPARATOR
Intervention: Olive oil placebo daily for one year
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: 20 ml HiEPA fish oil
Number of subjects: 87
Study: 6233921

Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine (20 micrograms, three doses)
Number of subjects: 1330

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1330
Study: 31525488

Group type: EXPERIMENTAL
Intervention: Specific communication tools (website, brochure, posters, signboard)
Number of subjects: 2100
Study: 29589873

Group type: EXPERIMENTAL
Intervention: Hydromorphone
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Diacetylmorphine
Number of subjects: 202

Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 202
Study: 27305424

Group type: EXPERIMENTAL
Intervention: Routine group (50μg fentanyl before colonoscopy)
Number of subjects: 119

Group type: COMPARATOR
Intervention: On-demand group (50μg fentanyl if needed during colonoscopy)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Routine group
Number of subjects: 119

Group type: COMPARATOR
Intervention: On-demand group
Number of subjects: 119
Study: 24801452

Group type: EXPERIMENTAL
Intervention: Total arterial compliance (C T)
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Carotid-to-femoral pulse wave velocity (PWV)
Number of subjects: 279
Study: 22443122

Group type: EXPERIMENTAL
Intervention: Airborne particle abrasion
Number of subjects: 240

Group type: COMPARATOR
Intervention: ZirLiner application
Number of subjects: 240

Group type: COMPARATOR
Intervention: No surface treatment
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Cyclic loading
Number of subjects: 240
Study: 20602892

Group type: EXPERIMENTAL
Intervention: Micronutrients supplement
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study: 18614731

Group type: EXPERIMENTAL
Intervention: Methionine intake ranging from 10 to 120 mg x kg(‐1) x d(‐1)
Number of subjects: 15
Study: 16372879

Group type: EXPERIMENTAL
Intervention: Breast cancer vaccines
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard breast cancer drugs or novel immunotherapeutics
Number of subjects: 0
Study: 12296776

Group type: EXPERIMENTAL
Intervention: Nd:YAG laser treatment
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo (nonactivated laser)
Number of subjects: 17
Study: 10570638

Group type: EXPERIMENTAL
Intervention: Histamine
Number of subjects: 16
Study: 8842630

Group type: EXPERIMENTAL
Intervention: SAM (Composite International Diagnostic Interview‐Substance Abuse Module)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SAM/SAM (test/retest)
Number of subjects: 0

Group type: COMPARATOR
Intervention: SAM/SCAN (test/validation)
Number of subjects: 0
Study: 2065809

Group type: EXPERIMENTAL
Intervention: 75% serum
Number of subjects: 194

Group type: COMPARATOR
Intervention: 8% serum
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: 2.25% human serum albumin (HSA)
Number of subjects: 194
Study: 6306094

Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ranitidine and antacids
Number of subjects: 0
Study: 30702996

Group type: EXPERIMENTAL
Intervention: Lomitapide, mipomersen, AAV8.TBG.hLDLR, inclisiran, bempedoic acid, gemcabene
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alipogene tiparvovec, pradigastat, volanesorsen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: evinacumab, IONIS‐ANGPTL3‐LRx
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IONIS‐APO(a)‐LRx
Number of subjects: 0
Study: 29389671

Group type: COMPARATOR
Intervention: Primaquine (15 mg, n = 5)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Artefenomel (500 mg, n = 4)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Untreated controls (n = 7)
Number of subjects: 17
Study: 26067095

Group type: EXPERIMENTAL
Intervention: Family presence during invasive nursing procedures
Number of subjects: 138

Group type: COMPARATOR
Intervention: No family presence during invasive nursing procedures (Control)
Number of subjects: 138
Study: 25115438

Group type: EXPERIMENTAL
Intervention: Daily dosing of 2000 IU of vitamin D3 per day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monthly dosing of 40,000 IU of vitamin D3 per month
Number of subjects: 0
Study: 22289281

Group type: EXPERIMENTAL
Intervention: Esmolol (50 μg/kg/min)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Phenylephrine (0.01 μg/kg/min)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (conventional anesthetic drugs and 20 ml/kg of lactated Ringer's over 30 mins)
Number of subjects: 60
Study: 19285832

Group type: EXPERIMENTAL
Intervention: Home training alone or supervised practice prior to home training
Number of subjects: 13

Group type: COMPARATOR
Intervention: Supervised practice
Number of subjects: 13

Group type: COMPARATOR
Intervention: Home training
Number of subjects: 13
Study: 17254365

Group type: EXPERIMENTAL
Intervention: Single session of behavioural treatment (n=16)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Repeated assessments (RA; n=15)
Number of subjects: 31
Study: 15008926

Group type: EXPERIMENTAL
Intervention: Early loading of ITI implants (2 weeks after placement)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (5 weeks after placement)
Number of subjects: 27
Study: 11079508

Group type: EXPERIMENTAL
Intervention: Low salt diet (LSD)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Normal salt diet (NSD)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: High salt diet (HSD)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (without EIA)
Number of subjects: 16
Study: 9589363

Group type: EXPERIMENTAL
Intervention: 125 mg oltipraz daily
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: 500 mg oltipraz weekly
Number of subjects: 234

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 234
Study: 8448097

Group type: EXPERIMENTAL
Intervention: Low Volume (LV) group: 1.5 to 2 mL per hour of bupivacaine 0.5% with sufentanil 4 micrograms/mL
Number of subjects: 30

Group type: COMPARATOR
Intervention: High Volume (HV) group: 6 to 8 mL per hour of bupivacaine 0.125% with sufentanil 1 microgram/mL
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study: 2427843

Group type: EXPERIMENTAL
Intervention: Celiprolol 200 mg once daily
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Celiprolol 400 mg once daily
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Celiprolol 600 mg once daily
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 3384951

Group type: EXPERIMENTAL
Intervention: Mixed meals containing 0, 8, 16, 24, and 32 kcal/kg fat‐free mass
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Caloric intake
Number of subjects: 0
Study: 31145324

Group type: EXPERIMENTAL
Intervention: Patient-centered educational strategy
Number of subjects: 170

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 170
Study: 28450552

Group type: EXPERIMENTAL
Intervention: Bilateral internal mammary arteries (BIMA)
Number of subjects: 3102

Group type: COMPARATOR
Intervention: Single internal mammary arteries (SIMA)
Number of subjects: 3102

Group type: EXPERIMENTAL
Intervention: BIMA
Number of subjects: 3102
Study: 26212007

Group type: EXPERIMENTAL
Intervention: IIV-HD
Number of subjects: 31989

Group type: COMPARATOR
Intervention: IIV-SD
Number of subjects: 31989
Study: 23294052

Group type: EXPERIMENTAL
Intervention: OFC (olanzapine + fluoxetine)
Number of subjects: 994

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 994
Study: 21464252

Group type: EXPERIMENTAL
Intervention: Intravenous peramivir 300 mg/day
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Intravenous peramivir 600 mg/day
Number of subjects: 37

Group type: COMPARATOR
Intervention: Safety analysis set (42 patients)
Number of subjects: 37
Study: 18349029

Group type: EXPERIMENTAL
Intervention: XELOX + Cetuximab
Number of subjects: 74

Group type: COMPARATOR
Intervention: XELOX
Number of subjects: 74
Study: 17998674

Group type: COMPARATOR
Intervention: Radiotherapy alone (6500 cGy/30 fractions)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (Cisplatin 80 mg/m2 on day 1 and Etoposide 100 mg/m2 on days 1-3, q3 weeks for 3 cycles) followed by radiotherapy (6000 cGy/30 fractions) and 3 more cycles of the same chemotherapy regimen
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Radiotherapy (5000 cGy/25 fractions) with concurrent chemotherapy (cisplatin 20 mg/m2 + Etoposide 75 mg/m2 on days 1-5 and days 22-26), followed by 2 more cycles of chemotherapy, q3 weeks with the same regimen
Number of subjects: 103
Study: 12737444

Group type: EXPERIMENTAL
Intervention: Oral budesonide (3 mg three times daily for 8 days)
Number of subjects: 20
Study: 11090233

Group type: EXPERIMENTAL
Intervention: Osteoporosis at the PA spine
Number of subjects: 1494

Group type: EXPERIMENTAL
Intervention: Osteoporosis at the femoral neck
Number of subjects: 1494

Group type: EXPERIMENTAL
Intervention: Osteoporosis at the midforearm
Number of subjects: 1494

Group type: EXPERIMENTAL
Intervention: BMD cutoff levels for osteoporosis
Number of subjects: 1494

Group type: EXPERIMENTAL
Intervention: Upper cutoff level for osteopenia
Number of subjects: 1494
Study: 9198795

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock waves
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 7967322

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate, 10 mg (ID)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Nifedipine, 20 mg (N)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Propranolol, 40 mg (P)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Combination of ID, 10 mg + P, 40 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Combination of N, 20 mg + P, 40 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Combination of ID, 10 mg + N, 20 mg
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 3514491

Group type: EXPERIMENTAL
Intervention: Dihydroergotamine (time-release preparation)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31242300

Group type: EXPERIMENTAL
Intervention: fIPV, 0.1 mL im
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: fIPV, 0.2 mL im
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: fIPV, 0.1 mL id
Number of subjects: 196

Group type: COMPARATOR
Intervention: IPV, 0.5 mL im
Number of subjects: 196
Study: 29440159

Group type: EXPERIMENTAL
Intervention: Hip arthroscopy with capsular closure
Number of subjects: 200

Group type: COMPARATOR
Intervention: Hip arthroscopy without capsular closure
Number of subjects: 200
Study: 27142077

Group type: EXPERIMENTAL
Intervention: Early potent, largely type I interferon-mediated response
Number of subjects: 115

Group type: COMPARATOR
Intervention: Modest type I interferon response
Number of subjects: 115

Group type: COMPARATOR
Intervention: Protracted cytokine response after seroconversion
Number of subjects: 115
Study: 23709329

Group type: EXPERIMENTAL
Intervention: 23-G microincision vitrectomy surgery (MIVS)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 25-G microincision vitrectomy surgery (MIVS)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Comparison of 23-G and 25-G MIVS
Number of subjects: 50
Study: 23186329

Group type: EXPERIMENTAL
Intervention: Screening + Assessment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Screening + Assessment + Brief Intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Minimal Screening Only
Number of subjects: 0
Study: 20222003

Group type: EXPERIMENTAL
Intervention: Endurance training (E)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Strength training (S)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Combined training (SE)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 79
Study: 18678294

Group type: EXPERIMENTAL
Intervention: Aspirin 300 mg/day
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Combined aspirin 100 mg/day plus clopidogrel 75 mg/day
Number of subjects: 151
Study: 15971716

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 12759722

Group type: EXPERIMENTAL
Intervention: Quinapril
Number of subjects: 96

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Both Quinapril and Atenolol
Number of subjects: 96
Study: 11232513

Group type: EXPERIMENTAL
Intervention: Kangaroo Care (KC)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Incubator (Control)
Number of subjects: 29
Study: 9493476

Group type: EXPERIMENTAL
Intervention: Sertraline (50 to 200 mg/day for 10 to 20 days)
Number of subjects: 3

Group type: COMPARATOR
Intervention: CYP3A substrates (alprazolam, carbamazepine, terfenadine)
Number of subjects: 3
Study: 8177920

Group type: EXPERIMENTAL
Intervention: Nimodipine (active drug)
Number of subjects: 12
Study: 3530364

Group type: EXPERIMENTAL
Intervention: Co-trimoxazole for 10 days
Number of subjects: 162

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study: 31599955

Group type: EXPERIMENTAL
Intervention: Nutrient-enriched donor milk (≥120 mL·kg‐1·d‐1)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Preterm formula
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: In-hospital mother's milk intake
Number of subjects: 158
Study: 29914380

Group type: EXPERIMENTAL
Intervention: VASP-guided clopidogrel maintenance therapy titrated by platelet reactivity index (PRI)
Number of subjects: 503

Group type: COMPARATOR
Intervention: Control group with fixed clopidogrel maintenance dose of 75 mg per day
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: VASP-guided clopidogrel maintenance therapy
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 503
Study: 28366170

Group type: EXPERIMENTAL
Intervention: 7 days of ciprofloxacin 500 mg orally twice daily
Number of subjects: 200

Group type: COMPARATOR
Intervention: 14 days of ciprofloxacin 500 mg orally twice daily
Number of subjects: 200
Study: 26181766

Group type: EXPERIMENTAL
Intervention: Aerobic Exercise (AE) for 3 months (n = 30)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Resistance Exercise (RE) for 3 months (n = 27)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group (n = 24)
Number of subjects: 81
Study: 24189336

Group type: EXPERIMENTAL
Intervention: Combination gait training (robot-assisted treadmill training followed by conventional body-weight-supported treadmill training)
Number of subjects: 7
Study: 20482934

Group type: EXPERIMENTAL
Intervention: neurocognitive training
Number of subjects: 116

Group type: COMPARATOR
Intervention: control condition
Number of subjects: 116
Study: 18319635

Group type: EXPERIMENTAL
Intervention: Calorie restriction program (n=36)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Healthy diet weight maintenance control (1 group)
Number of subjects: 48
Study: 16800988

Group type: EXPERIMENTAL
Intervention: Ganbi decoction (GBD)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Glucuronolactone tablets and inosine injection (Control)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 128
Study: 14665354

Group type: EXPERIMENTAL
Intervention: 50 mg of oral rofecoxib
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 10435202

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Worsening on the PANSS depression cluster
Number of subjects: 0
Study: 9084325

Group type: EXPERIMENTAL
Intervention: 10% CHX gel in gel trays on two consecutive days, followed by application of a fluoride varnish (Group A)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 10% CHX gel (Group B)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (Group C)
Number of subjects: 24
Study: 1679047

Group type: EXPERIMENTAL
Intervention: Xamoterol (200 mg twice daily)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Xamoterol
Number of subjects: 51
Study: 7104176

Group type: EXPERIMENTAL
Intervention: Spironolactone 50 mg daily
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Spironolactone 100 mg daily
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Triamterene 100 mg daily
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Triamterene 200 mg daily
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Potassium chloride 32 mmol daily
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Potassium chloride 64 mmol daily
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 31434037

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (FF) 100 mcg
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 27940287

Group type: EXPERIMENTAL
Intervention: Glycopyrronium 44 μg
Number of subjects: 152

Group type: COMPARATOR
Intervention: Tiotropium 18 μg
Number of subjects: 152
Study: 25501868

Group type: EXPERIMENTAL
Intervention: Apixaban 50 mg QD for 3 days
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Apixaban 10 mg QD for 3 days
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg on Day 3
Number of subjects: 40

Group type: COMPARATOR
Intervention: Matched apixaban placebo QD for 3 days
Number of subjects: 40